Skip to main content

Table 4 Survival analysis for invasive disease-free survival

From: Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

Variables    Univariate analysis Multivariate analysis
P HR 95% CI P HR 95% CI
Age, years ≥50 < 40 0.330 1.629 0.611–4.341    
Menopausal status Post Pre 0.903 1.068 0.371–3.077    
Clinical stage 2B-3B 2A 0.007 0.010
  3C    
ER, Allred score 5–8 0–4 0.003 0.221 0.082–0.593 0.216 0.425 0.109–1.651
PR, Allred score 5–8 0–4 0.129 0.456 0.166–1.258 0.597 0.671 0.153–2.945
Ki67 index, % ≥ 14 < 14 0.039 3.300 1.064–10.241 0.309 1.949 0.540–7.037
Molecular subtype Luminal B-like Luminal A-like 0.091 2.650 0.854–8.221    
Regimens AC4T4 AC4 or TC4 0.599 21.513    
Surgery Mastectomy BCS 0.110 3.348 0.760–14.746    
pSUVmax ≥ 9.55 <  9.55 0.427 1.493 0.555–4.014 0.580 0.702 0.201–2.455
Pathologic CR Yes No 0.066 3.281 0.924–11.650 0.137 3.170 0.693–14.513
  1. Abbreviations: ER Estrogen receptor, PR Progesterone receptor, pSUVmax SUVmax of primary breast tumor, CR Complete response, AC Anthracycline + cyclophosphamide, T Taxane, TC Docetaxel + cyclophosphamide, BCS Breast conserving surgery, HR Hazard ratio, CI Confidence interval
\